Cordex exploring its strategic options

La Jolla, CA-based Cordex Pharma has invited in WBB Securities to help it take a look at its strategic alternatives. "We believe that we can best serve the interests of all our shareholders by exploring every possible alternative to enhance shareholder value," Cordex CEO Shepard Goldberg says in a release. The developer's lead therapy has an approved SPA to enter a pivotal Phase IIb/III clinical trial for the treatment of a common heart arrhythmia called paroxysmal supraventricular tachycardia. Release

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.